On July 23, CMBC CAPITAL fell 16.52% in regular trading, trading at 4.06 HKD/share, with turnover of approximately 118 million HKD. The stock had plunged 17.3% on July 21 following the expiry of Puqi Pharma's IPO prospectus, briefly rebounded on July 22, but failed to sustain gains and resumed its sharp decline today.

On the news front, Puqi Pharma's Hong Kong IPO prospectus officially expired on July 21 after the six-month validity period lapsed. CMBC CAPITAL served as one of the joint sponsors for the listing. The company's annual profit had surged 197.73% year-over-year to 151 million HKD, primarily driven by a significant increase in securities underwriting and sponsorship fee income. The failure of this sponsorship project to advance has triggered sustained market concerns over the durability of its core investment banking revenue stream. Additionally, southbound capital has continued to reduce holdings in recent sessions, intensifying near-term selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)